Clinical Trials

List clinical trials by disease

Search Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Melanoma. 7 results shown below.

Laboratory-Treated T Cells With or Without Ipilimumab in Treating Patients With Metastatic Melanoma

[Complete title: Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and anti-CTLA4 For Patients With Metastatic Melanoma]
Principal Investigator: Aude Chapuis, MD
Study Number: 2225.00
Phase: I/II

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

[Complete title: Multicenter Selective Lymphadenectomy Trial II (MSLT II): A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node]
Principal Investigator: David Byrd, MD
Study Number: 7108
Phase: III

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer

[Complete title: A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer]
Principal Investigator: John Thompson, MD
Study Number: 7637a
Phase: I

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

[Complete title: A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination with Ipilimumab in Subjects with Unresectable Stage III or Stage IV Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20111942
Phase: I

Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma

[Complete title: An Exploratory Study of the Biologic Effects of BMS-936558 (Anti-PD-1 Monoclonal Antibody) Treatment in Subjects with Advanced Melanoma (Unresectable or Metastatic)]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20122036
Phase: I

Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors (MDX1105-01)

[Complete title: A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors (WIRB's Study#: 1107927, Protocol#: 20082100)]
Principal Investigator: Scott Tykodi, MD
Study Number: 7104
Phase: I

Trial of pIL-12 Electroporation Malignant Melanoma (IL12MEL)

[Complete title: A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7703
Phase: II

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.